BioCentury
ARTICLE | Clinical News

Aerpio begins Phase IIb of AKB-9778 in diabetic retinopathy

July 28, 2017 6:13 AM UTC

Aerpio Pharmaceuticals Inc. (Cincinnati, Ohio) began the Phase IIb TIME-2b trial to evaluate once- and twice-daily 15 mg subcutaneous AKB-9778 for 12 months in about 150 patients with moderate to severe non-proliferative diabetic retinopathy.

The primary endpoint of the double-blind, placebo-controlled, U.S. trial is the percentage of patients with a ≥2-step improvement on the diabetic retinopathy severity scale (DRSS) in the study eye. Secondary endpoints include safety and change in DRSS score in the study eye, the fellow eye and both eyes. ...

BCIQ Company Profiles

Aerpio Pharmaceuticals Inc.